Lexaria Bioscience (LEXX) Receives New Patents

• Total of 6 new granted patents received by Lexaria so far in 2023
• Lexaria now holds 34 granted patents world-wide

Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) announces that it has received notifications of four new granted patents.

Lexaria has been granted a new Canadian patent under our Patent Family #1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof. This is Lexaria's 18^th patent in this Patent Family and our first patent for this Patent Family issued in Canada.

Also in Canada, Lexaria has been granted a new patent under our Patent Family #8: Compositions Infused with Nicotine Compounds and Methods of Use Thereof which was previously announced as "allowed" on April 20, 2023. This is Lexaria's second patent in this Patent Family, following a similar patent issuance in Australia in 2022.

Lexaria has also been granted two new US patents under our Patent Family #21. The first being for Pharmaceutical Compositions and Methods for Treating Hypertension; and the second being for Compositions and Methods for Treating Hypertension, which was previously announced as "allowed" on April 20, 2023. Lexaria points out that one of these patent awards is specifically for pharmaceutical compositions while the other patent award is for non-pharmaceutical compositions, each of which reinforce Lexaria's commercial opportunities in the separate pharmaceutical and consumer markets.

Lexaria believes these two hypertension-related patents could be of particular importance related to the Company's pursuit of utilizing DehydraTECH-CBD in relation to our expected upcoming FDA Investigational New Drug application. The outcomes of our completed HYPER-H21 series of hypertension studies were instrumental in achieving these patent grants. These are Lexaria's first and second granted patents in this Patent Family #21.

The global cardiovascular drugs market was worth US$146.5 billion in 2022 and expected to reach $173.5 billion in 2026 and by geography, North America is the biggest market in the world making US patent protection a necessity in the pursuit of commercial markets.

You May Also Be Interested In

• Strata Mental Health gets Compass Pathways grant for COMP360 training
• Spectral Medical gets FDA feedback on PMX device application
• Corning (GLW) files for up to $2B offering of common shares